Advent Technologies Holdings Inc (ADN)

[WeTheMarket]

Form 424B5 - Prospectus [Rule 424(b)(5)]
December 27 2023
https://ih.advfn.com/stock-market/NASDAQ/advent-technologies-ADN/stock-news/92895349/form-424b5-prospectus-rule-424b5

PROSPECTUS SUPPLEMENT
(To Prospectus dated May 2, 2023)

ADVENT TECHNOLOGIES HOLDINGS, INC.

10,000,000 shares of Common Stock

This prospectus supplement and the accompanying prospectus relate to the offer and sale of 10,000,000 shares of our Common Stock, par value $0.0001 per share (the “Common Stock”). Shares of our Common Stock to which this prospectus supplement relates will be issued in a privately negotiated transaction pursuant to the terms of a Securities Purchase Agreement we have entered into with John Nash, Scott Dols, Timothy Beckett, the Kantor Family Trust, BJI Financial, and the Cavalry Fund (collectively, the “Purchasers”). We are offering the Common Stock at a combined purchase price of $2,000,000.

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “ADN.” On December 26, 2023, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $0.2033 per share.

We have engaged Joseph Gunnar & Co., LLC (the “placement agent”) to act as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered in this offering. The placement agent is not purchasing or selling any of the securities we are offering, and the placement agent is not required to arrange the purchase or sale of any specific number of securities or dollar amount. There is no required minimum number of securities that must be sold as a condition to completion of this offering, and there are no arrangements to place the funds in an escrow, trust, or similar account. See “Plan of Distribution” beginning on page S-18 of this prospectus supplement for more information regarding these arrangements.